MPN Watch

Dossier pubmed other 30-jul-2026

Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Key claim: This item is an erratum correcting the Phase III SENTRY trial report of selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis.

Abstract

No abstract available.

Why this matters

This item is an erratum correcting the Phase III SENTRY trial report of selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis.

Source

Link

Briefing card

Erratum: Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.
Stage: other · pubmed · 30-jul-2026

This item is an erratum correcting the Phase III SENTRY trial report of selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

🔎 Pulled in by auto-added search #31 (pubmed): "selinexor"[Title/Abstract] AND "ruxolitinib"[Title/Abstract] AND ("myelofibrosis"[Title/Abstract] OR "myeloproliferative"[Title/Abstract])

External: doi:10.1200/JCO-26-01827

Ask about this finding

Replies are grounded in the abstract and metadata above. The model will quote directly when possible and say so if a question isn't covered.

Subscribe: calendar of upcoming dates · deadlines feed · all new records · Help

build build 612 · 69ce4cf-dirty · 2026-11-11